Project Grant R00CA296780
Award Date 6/1/26
Completion Date 5/31/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Broad Institute of MIT and Harvard a $795,544 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, with completion targeted for July 31, 2027. This award funds the development of computational methods for profiling the cancer virome and microbial strain genetics from shotgun metagenomes and metatranscriptomes. The deliverables include novel algorithms that integrate...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $669,278 to the University of Michigan's Office of Research and Sponsored Projects, effective June 1, 2026 through May 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This Multi-Principal Investigator (MPI) R01 application, aligned with PAR-25-107 (Advancing Microbial-Based Cancer Therapy), supports the development of engineered nonpathogenic tumor-tropic E. coli bacteria...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $687,593 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on May 12, 2026, with completion targeted for April 30, 2031. The award funds fundamental cancer biology research investigating cysteine acquisition and utilization mechanisms in lung adenocarcinoma. The research will deliver scientific insights into how tumor cells...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a Project Grant of $640,775 under the Cancer Treatment Research program (CFDA 93.395) on June 22, 2026, with a completion date of May 31, 2031. The grant supports a co-clinical trial investigating the role of intratumoral bacteria in driving immunosuppression and immune checkpoint inhibitor (ICI) resistance in head and neck squamous cell carcinoma...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $660,541 to The University of Texas MD Anderson Cancer Center for research under the Cancer Biology Research program (CFDA 93.396). The award, effective April 1, 2026, through March 31, 2031, supports fundamental research on the modulation of the tumor microenvironment by Fusobacterium nucleatum (FN) and co-infecting microbial species in colorectal cancer (CRC). The research addresses a critical...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1.098 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on August 13, 2025, with a completion date of April 30, 2030. The funded research focuses on understanding the biological mechanisms controlling CD8+ tumor-infiltrating lymphocytes (TILs) and their progression through various functional states, including...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Project Grant Award Summary The National Cancer Institute awarded $399,829 to the University of North Carolina at Chapel Hill under the Cancer Biology Research program (CFDA 93.396) for a two-year project (September 1, 2025–August 31, 2027) investigating the role of Fusobacterium nucleatum in breast cancer progression and therapeutic resistance. The research will characterize how this bacterium, detected in approximately 30% of breast cancer cases, alters the tumor microenvironment and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $688,073 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. The award funds computational research to reconstruct the evolutionary history of cancer metastases, led by Principal Investigator Dr. Peter Van Loo. The project develops novel molecular archeology of cancer approaches—computational methods that leverage DNA sequencing...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...